Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
NCT05081245Phase 2Completed
- Sponsor
- MapLight Therapeutics
- Start
- Sep 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of ML-004 in Autism Spectrum Disorder (ASD), sponsored by MapLight Therapeutics. Started Sep 2022; status: completed.
02
Drugs
ML-004
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT05081245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05081245.